Clinical efficacy and safety of minocycline in the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children of different age groups
10.3760/cma.j.cn311365-20250531-00162
- VernacularTitle:米诺环素治疗不同年龄段儿童大环内酯类耐药肺炎支原体肺炎的临床疗效及安全性
- Author:
Hua XU
1
;
Shiyu HUANG
1
;
Yajuan ZHOU
1
;
Qing CAO
1
Author Information
1. 上海交通大学医学院附属上海儿童医学中心感染科，上海 200127
- Publication Type:Journal Article
- Keywords:
Children;
Minocycline;
Mycoplasma pneumoniae pneumonia;
Clinical efficacy
- From:
Chinese Journal of Infectious Diseases
2025;43(10):577-583
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the clinical efficacy and safety of minocycline in the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMP) in children of different age groups. Methods:The clinical data of MRMP cases treated with minocycline hydrochloride capsules in the Department of Infectious Diseases of Shanghai Children′s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine from June 2023 to June 2024 were collected through the hospital′s electronic medical record system. This study used a retrospective cohort study. According to the age of onset, they were divided into two groups: children <8 year-old-group and those ≥8 year-old-group. The indicators including the duration of temperature after medication, the recovery time of serum amyloid A (SAA) and C-reactive protein (CRP) were compared between the two groups. The adverse reactions during hospitalization and follow-up of six months after discharge were analyed. Non-parametric rank sum test was used for statistical comparison.Results:A total of 274 MRMP cases were included, including 151 in the <8-year-old group and 123 in the ≥8-year-old group. After minocycline hydrochloride capsule treatment, the duration of fever in the ≥8-year-old group was 1.5(1.0, 2.0) d, which was shorter than 2.0(1.0, 2.0) d in the <8-year-old group. The difference was statistically significant ( Z=-2.02, P=0.044). The recovery time for SAA (3.0(2.0, 6.0) d vs 5.0(3.0, 6.0) d) and CRP (3.0(2.0, 5.0) d vs 4.0(3.0, 6.0) d) in the <8-year-old group were both shorter than those in the ≥ 8-year-old group, and the differences were both statistically significant ( Z=-2.62, P=0.009 and Z=-3.10, P=0.002, respectively). During hospitalization, there were two cases of nausea, four cases of vomiting, one case of abdominal pain, with no rash, dizziness and tetracycline teeth in the <8-year-old group, and the incidence of adverse reactions was 4.6%(7/151). In the ≥8-year-old group, there were one case of nausea, one case of vomiting, one case of rash, one case of dizziness, with no abdominal pain and tetracycline teeth, and the incidence of adverse reactions was 3.3%(4/123). There were 253 cases of follow-up, of which 148 cases (58.5%) did not re-examine because of the normal blood routine at the last time during hospitalization, 105 cases (41.5%) re-examined blood routine, and the results were all normal. Twenty-five cases were normal in liver and kidney functions. Some children under six years old who did not change permanent teeth failed to clarify the impact of minocycline on teeth due to the short follow-up time. The total effective rate of minocycline in the two groups was consistent, both was 100.00%. Conclusions:Minocycline has a good clinical efficacy for MRMP. The total effective rate of clinical treatment for MRMP in children <8 years old and ≥8 years is consistent, with fewer adverse reactions and good safety. The impact on the teeth of children under six years old who have not replaced their deciduous teeth with permanent teeth requires further observation.
